What Lies Beneath: Current and Emerging Treatments for Prurigo Nodularis

Program Overview

Patients with prurigo nodularis (PN) can often go for years undiagnosed, misdiagnosed, and as a result, not properly managed. In this Care Team Forum®, we hear firsthand from Tiwana on how it was like living with PN, the impact it has had on her life, her experience seeking medical care, and how she integrates her therapeutic plan into her life. Joining her in discussion are Drs. Shawn Kwatra, Sarina Elmariah, and Sarah Chisolm who will discuss PN from a pathophysiological perspective, highlighting the role of type 2 inflammation, current and newly approved treatment options, as well as emerging therapies for PN.

Credit Expired

Target Audience

Dermatology and primary care clinicians

Educational Objectives

Upon completion of this activity, participants should be better able to:

Identify elements of type 2 inflammation that play a role in prurigo nodularis (PN) pathogenesis that may be amenable to treatment
Examine the impact of current and emerging therapies on the management of PN

Activity Faculty

Shawn Kwatra, MD

Associate Professor, Dermatology and Oncology
Director, Johns Hopkins Itch Center
Johns Hopkins University School of Medicine
Baltimore, MD

Sarah S. Chisolm, MD

Assistant Professor and Director, Clinical Trials, Department of Dermatology
Emory University
Managing Director, ITCH-E (Itch Translational and Clinical Home at Emory)
Staff Physician, VISN 7, VA
Emory University Hospital
Atlanta, GA

Sarina B. Elmariah, MD, PhD, MPH

Associate Professor, Dermatology
Director, UCSF Center for Itch and Neurosensory Disorders
University of California, San Francisco
San Francisco, CA